Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma

Pandyarajan, Vijay; Govalan, Rajalakshmi; Yang, Ju Dong

doi:10.3390/ijms22020479

Cited by 29 publications

(17 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AFP can re ect liver damage and prognosis, which is closely associated with liver function. [16][17][18] The level of AFP in patients with abnormal liver function is signi cantly higher than that in patients with normal liver function. The results of this study show that AFP level is a risk factor for hepatocellular carcinoma with hypoglycemia.…”

Section: Demographic and Clinical Characteristicsmentioning

confidence: 99%

Incidence and risk factors for hypoglycemia in patients with hepatocellular carcinoma

Zheng

Yan

Gan

et al. 2021

Preprint

View full text Add to dashboard Cite

AimTo evaluate the incidence and risk factors for hypoglycemia in patients with hepatocellular carcinoma (HCC).MethodsWe collected and analyzed the clinical data of patients with HCC in our cancer center between April 2020 and June 2021. Univariate and multivariate logistic regression analyses were performed to identify the risk factors associated with hypoglycemia.ResultsThe incidence rate of hypoglycemia in patients with HCC was 28.9% (67/232). Multivariate logistic regression analysis showed a significant association between hypoglycemia and Child-Pugh grade C (odds ratio [OR]=7.3, 95% confidence interval [CI] 2.28–23.31, p=0.001), alpha-fetoprotein (AFP) level (OR=1.000035, 95% CI 1.000007–1.000063, p=0.015), and glycated hemoglobin (HbA1c) level (OR=0.46, 95% CI 0.29–0.73, p=0.001).ConclusionChild-Pugh stage and HbA1c and AFP levels were associated with hypoglycemia in patients with HCC. Our study suggests that these three factors should be comprehensively considered when estimating the risk of hypoglycemia in these patients, and the diagnosis, treatment, and nursing plan should be adjusted in time to reduce the incidence of hypoglycemia.

show abstract

Section: Demographic and Clinical Characteristicsmentioning

confidence: 99%

Incidence and risk factors for hypoglycemia in patients with hepatocellular carcinoma

Zheng

Yan

Gan

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…This results in further diversification and progression of the tumor[ 9 ]. Additionally, several other biomarkers namely, glypican-3, Golgi protein complex-73, squamous cell carcinoma antigen and circulating tumor DNA are useful for early diagnosis of HCC, and might be clinically validated in the near future[ 10 ].…”

Section: To the Editormentioning

confidence: 99%

Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota

Nath¹,

Murali²,

Nair³

2021

WJGO

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and one of the major causes of cancer-related death. The development of specific non-invasive or diagnostic markers from blood, urine and feces may represent a valuable tool for detecting HCC at an early stage. Biomarkers are considered novel potential targets for therapeutic intervention. It helps in the prediction of prognosis or recurrence of HCC, and also assist in the selection of appropriate treatment modality. We summarize the most relevant existing data about various biomarkers that play a key role in the progression of HCC.

show abstract

“…Liver cancer is a complex disorder and one of the most prevalent malignant tumours in the digestive system. It is caused by multiple factors, and the primary pathological type is hepatocellular carcinoma (HCC) 1 , 2 . According to 2018 global cancer statistics, liver cancer is the 4th leading cause of cancer death 3 .…”

Section: Introductionmentioning

confidence: 99%

ADAM12 is an independent predictor of poor prognosis in liver cancer

Sun

Wang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Disintegrin and metalloproteinase 12 (ADAM12) is thought to trigger the occurrence and development of numerous tumours, including colorectal, breast, and pancreatic cancers. On the basis of The Cancer Genome Atlas (TCGA) datasets, in this study, the relationship between ADAM12 gene expression and hepatocellular carcinoma (HCC), the prognostic value of this relationship, and the potential mechanisms influencing HCC development were evaluated. The results showed that the ADAM12 gene was significantly and highly expressed in liver cancer tissue. The high expression of the ADAM12 gene in liver cancer tissue significantly and positively correlated with T stage, pathological stage, and residual tumour. Kaplan–Meier and Cox regression analyses revealed that ADAM12 gene expression is an independent risk factor influencing the prognosis of patients with liver cancer. Pathway analyses of ADAM12 in HCC revealed ADAM12-correlated signalling pathways, and the expression level of ADAM12 was associated with immune cell infiltration. In vitro experiments demonstrated that the expression level of ADAM12 in Huh-7 and Hep3B cells was significantly higher than that in other HCC cells. ShRNA transfection experiments confirmed that the expression levels of TGF-β and Notch pathway-related proteins were significantly decreased. An EdU cell proliferation assay showed that a low level of ADAM12 gene expression significantly inhibited the proliferative activity of HCC cells. Cell cycle experiments showed that low ADAM12 expression blocked the G1/S phase transition. Overall, this research revealed that high ADAM12 gene expression implies a poor prognosis for patients with primary liver cancer. In addition, it is a potential indicator for the diagnosis of liver cancer.

show abstract

Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma

Cited by 29 publications

References 135 publications

Incidence and risk factors for hypoglycemia in patients with hepatocellular carcinoma

Incidence and risk factors for hypoglycemia in patients with hepatocellular carcinoma

Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota

ADAM12 is an independent predictor of poor prognosis in liver cancer

Contact Info

Product

Resources

About